Verrica Pharmaceuticals Inc. Common Stock
VRCAVerrica Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing dermatology solutions. The company's lead products target FDA-approved indications for the treatment of skin conditions caused by viruses, such as molluscum contagiosum and common warts. Verrica aims to address unmet medical needs with innovative and well-tolerated therapies for dermatological issues.
Company News
Verrica Pharmaceuticals announced the first patient dosing in a global Phase 3 clinical trial for YCANTH (VP-102) to treat common warts, a condition affecting approximately 22 million patients in the U.S. with no FDA-approved prescription therapies. The Phase 3 program is based on positive Phase 2 COVE-1 results showing 51% complete clearance of ...
Verrica Pharmaceuticals reported strong Q2 2025 financial results, with non-GAAP EPS of $0.25 and GAAP revenue of $12.7 million, significantly exceeding analyst expectations. The company saw improved performance driven by YCANTH product sales and a major milestone payment from Torii Pharmaceutical.
Verrica Pharmaceuticals announced the acceptance of two abstracts featuring positive preliminary results from a Phase 2 study of its investigational therapy VP-315 for the treatment of basal cell carcinoma. The data showed promising safety, tolerability, and antitumor efficacy.
Verrica Pharmaceuticals reported Q2 2024 financial results, including $4.9M in YCANTH revenue and positive preliminary results from a Phase 2 study of VP-315 for basal cell carcinoma. The company also announced progress in its common warts program and expansion of YCANTH distribution.
- Dormer Labs has discontinued the sale of all cantharidin-containing products into the United States
